IN THE CLAIMS

This claim listing replaces all the previous claim listings.

1. (Previously cancelled)

2. (Currently amended) A cyclic peptide having an amino acid sequence C*C*RGDVLDC* , where asterisks denote to places of possible disulfide bonds, said sequence corresponding to apoptotically active site of human alpha-fetoprotein localized at amino acid residues 251-259 of said protein ~~structure with a general formula of CCRGDVLD$_n$X$_m$Y in which formula X is any hydrophobic amino acid and Y is any hydrophilic amino acid, and the index n is 1, 2 or 3 and index m is 1, 2 or 3~~, said peptide having its cyclic structure through disulfide bonds between cystein residues corresponding to Cys251 and Cys259 of the protein and said peptide ~~structure~~ having a capability to regulate apoptotic cell death.

3. (Cancelled)

4. (Withdrawn) The peptide structure of Claim 3, wherein the peptide structure is further selected from a group consisting of linear and cyclic.

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Cancelled).

9. (Cancelled)

10. (Currently amended) A method for suppressing apoptotic regulatory pathways in human and animal cells by treating the cells with peptide ~~structures~~ according to claim 2 for an appropriate period of time.

11. (Withdrawn) A method to increase preservation of organs or cells within their transplantation by using the peptide structures of Claim 2.

12. (Withdrawn) A method to prevent autoimmune disorders and an immunodeficiency syndrome induced by a viral infection by use of the peptide structures of Claim 2.

13. (Withdrawn) A method to lower cytotoxic effects after chemo or radiotherapy by using the peptide structures of Claim 2.

14. (Currently amended) A method to inhibit cell apoptosis by using the peptide ~~structures~~ of Claim 2.

15. (Previously presented) The method according to claim 10, wherein the cells are cultured for scientific or technical purposes.

16. (Currently amended) The ~~molecular~~ peptide ~~structure~~ according to Claim 2, wherein the structure has an ability to bind into an antibody prepared against the molecular recognition site of a Fab-fragment or said anti-idiotypic antibody.

17. (Currently amended) The peptide ~~structure~~ of Claim 2, wherein the peptide is a dimer formed via disulfide bond between free cysteins of peptide monomers corresponding to Cys252 of human alpha phetoprotein ~~polymerized~~.

18. (cancelled)

19. (Cancelled)

20. (Withdrawn) The peptide structure of claim 18 wherein the structure is:



21. (Withdrawn) The peptide structure of claim 18, wherein the structure is:



22. (Previously presented) The method of claim 14, wherein the apoptosis is selected from the group consisting of neuronal cell apoptosis, non-specific drug-induced apoptosis, and oxidative stress –mediated apoptosis.